news
Study identifies pathway responsible for blood-brain barrier impairment in Alzheimer’s
The team found that the expression of the APOE4 gene variant in pericytes caused amyloid plaque formation in a blood-brain barrier model.
List view / Grid view
Therapeutics
news
Investigational anti-SARS-CoV-2 molecules show efficacy in pre-clinical studies
Pre-clinical testing of the COVIDTRAP™ (STI-4398) protein and STI-1499 antibody reveal they can inhibit SARS-CoV-2 from infecting cells.
article
Application of organoid technology for retinal disease modelling and drug discovery
The loss of retinal light-sensing photoreceptor cells is a leading cause of blindness and the number of individuals affected by retinal degenerative diseases is increasing with an ageing population. Currently, there are no treatments for these diseases and progress in finding new treatments is slow. This article explores the potential…
article
Using big data approaches to develop cell therapies
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
article
Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
article
Delivering a therapy to kerb COVID-19
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
article
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
article
Triplet immuno-oncology drug combinations – the future of treating multiple cancer
The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with…
news
Novel complement inhibitor improves ischemic stroke recovery in mice, say researchers
Administering a novel complement protein blocker (B4Crry) alongside reperfusion therapy improved cognitive and motor recovery in a model of ischemic stroke.
news
Cancer mutation could be used to target CRISPR therapy
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
news
Novel compound improves symptoms of fatty liver disease in mice
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin, increased glucose tolerance and lean body mass in a murine model of non-alcoholic fatty liver disease (NAFLD).
article
Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
article
Expert view: Delivering better therapeutics: fully characterising and recovering T cells
T cell-based therapies have shown promise as new treatment options for various cancers.
news
Flow synthesis technology enables faster protein production
The novel protocol allows proteins over 100 amino acids long to be synthesised in hours and include amino acids that do not occur in the human proteome.
whitepaper
Application note: High-throughput sialylation screening in combination with titer monitoring for expediting clone selection in cell-line development
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
